Scarica l'app Stockscreener
24.82
0.98%
0.24
Dopo l'orario di chiusura:
24.82
Precedente Chiudi:
$24.58
Aprire:
$24.26
Volume 24 ore:
1.18M
Relative Volume:
2.14
Capitalizzazione di mercato:
$1.38B
Reddito:
$2.50M
Utile/perdita netta:
$-131.12M
Rapporto P/E:
-8.7299
EPS:
-2.8431
Flusso di cassa netto:
$-112.73M
1 W Prestazione:
-4.06%
1M Prestazione:
-9.02%
6M Prestazione:
-51.39%
1 anno Prestazione:
+54.93%
Intervallo 1D:
$23.94
$25.62
Intervallo di 1 settimana:
$23.94
$26.57
Portata 52W:
$20.00
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
24.82 | 1.37B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-03-10 | Iniziato | Mizuho | Outperform |
| 2025-12-04 | Iniziato | Wells Fargo | Overweight |
| 2025-11-14 | Iniziato | Raymond James | Outperform |
| 2025-09-02 | Iniziato | BTIG Research | Buy |
| 2025-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Australia
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com Nigeria
Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com
Maze Therapeutics (MAZE) R&D chief exits direct stake - Stock Titan
Maze Therapeutics CEO Coloma Jason V Offloads 22,638 Shares at $25.77 to $27.12 Each - Kalkine Media
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
MAZE News | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
Courtney Phillips Executes 11,000 Zero-Cost Options in Maze Therapeutics (NASDAQ: MAZE) on September 1, 2026 - Kalkine Media
Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares to Cover RSU Tax Withholding - Kalkine Media
Maze Therapeutics (NASDAQ: MAZE) officer lines up new stock sale after recent 10b5-1 trades - Stock Titan
Maze Therapeutics Chief Executive Officer Sold Shares Worth Over $593K - TradingView
Maze Therapeutics (MAZE) legal chief sells stock for taxes - Stock Titan
Insider at Maze Therapeutics (MAZE) sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) CEO sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) R&D chief sells shares to cover RSU taxes - Stock Titan
Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - Kalkine
Maze Therapeutics Officer Courtney Phillips Reports RSU Vesting and Stock Settlement - Kalkine Media
Maze Therapeutics CEO Jason V Coloma Reports RSU Vesting and Trust Share Sales in Form 4 Filing - Kalkine Media
RSU vesting gives Maze Therapeutics (MAZE) exec 12,500 shares - Stock Titan
Maze Therapeutics (MAZE) CEO gets 50K shares, trims stake via trust sales - Stock Titan
Rule-based stock plan leads Maze Therapeutics (MAZE) exec to sell shares and log 20,000 RSUs - Stock Titan
Maze Therapeutics (MAZE) legal chief gets 11,000 shares - Stock Titan
Officer plans to sell up to $623K in Maze Therapeutics (MAZE) stock from vested RSUs - Stock Titan
Maze Therapeutics to Participate in Three Upcoming Investor Conferences - finance.yahoo.com
MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences - finance.yahoo.com
Maze Therapeutics CSBO Dandekar divests $206,823 of common stock - Investing.com India
Maze Therapeutics CSBO Dandekar divests $206,823 of common stock By Investing.com - Investing.com Canada
Maze Therapeutics (MAZE) exec sells 7,500 shares under 10b5-1 plan - Stock Titan
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates - Eastern Progress
MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update - finance.yahoo.com
MAZE Q1 2026 Earnings: 19.14% EPS Beat Tempers Loss but Shares Slip 2.76%Performance Review - vinanet.vn
Maze Therapeutics (MAZE) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Maze (MAZE) Latest: Finishes 1.73% Higher at $29.43 for the Current Session; Price Context: the Session Ends Within the Reported Technical Boundaries under the Current SnapshotBreak of Structure - vinanet.vn
Maze (MAZE) Levels: Rises 1.73% to $29.43 in the Latest Reading; Current Setup: the Session Ends Within the Reported Technical Boundaries in the Latest SessionPullback Trade - vinanet.vn
Maze (MAZE) Trading: Ends Lower by 4.18% at $28.50 in the Latest Session; Price Context: the $27.07 to $29.93 Range Remains in FocusMESA MA - vinanet.vn
Maze (MAZE) Price: Climbs 0.72% to $29.34 at the Close; Market Levels: Support at $27.87 and Resistance at $30.81 Frame the RangeVolume Oscillator - vinanet.vn
Trv Gp Iv LLC Invests $133.50 Billion in Maze Therapeutics, Inc. $MAZE - MarketBeat
Trv Gp V LLC Buys Shares of 950,800 Maze Therapeutics, Inc. $MAZE - MarketBeat
Alphabet Inc. Acquires New Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics Confirms MZE829 Data Readout for Late 2026 or Early 2027 - Minichart
Maze Therapeutics Names Paula A. Johnson and Sophie Kornowski to Board of Directors - Kalkine Media
Maze Therapeutics (MAZE) awards director 36,000 stock options - Stock Titan
Maze Therapeutics (MAZE) awards director 36K stock options - Stock Titan
Maze Therapeutics (NASDAQ: MAZE) director shows no stock or derivative holdings - Stock Titan
Maze Therapeutics (MAZE) director begins reporting with zero shares disclosed - Stock Titan
Maze Therapeutics Director Paula A. Johnson Awarded 36,000 Stock Options - Kalkine Media
Maze Therapeutics (MAZE) Pulls Back 1.75% as Shares Consolidate Above Key SupportMomentum Factor - vinanet.vn
128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Maze Therapeutics president sells $445,620 in company stock By Investing.com - Investing.com South Africa
Maze Therapeutics president sells $445,620 in company stock - Investing.com
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):